期刊文献+

HSP110及其免疫佐剂效应的研究进展 被引量:1

Research progress of HSP110 and its immune adjuvant effect
原文传递
导出
摘要 热休克蛋白(HSP)是一类在生物进化中高度保守、广泛存在于原核和真核生物中的蛋白质。大量资料表明,HSP作为分子伴侣,参与其它蛋白质的折叠、转运、合成等过程,并可与细胞内的其它蛋白质结合,参与细胞的抗损伤、修复和热耐受过程,某些热休克蛋白还具有佐剂效应,能够激活免疫应答反应,以往对于HSP70及其免疫治疗的研究较为广泛。近年来随着对热休克蛋白研究的不断深入,人们发现高分子量的HSP110因其强大的分子伴侣功能而具备独特的佐剂效应,因而被认为在瘤苗制备及抗肿瘤免疫中具有很大的应用前景。 Heat shock proteins (HSPs) are most highly conserved proteins in prokaryotes and eukarytes. A vgreat of data showed that HSPs act as molecular chaperones to regulate protein folding,transloeation, and assembly,it can combine with other proteins existing in cells and participate in the process of anti-damage, repair and thermotoleranee of cells, some HSPs can work as adjuvant and activate immune response. In the past, many researches focused on HSP70 and its role of immune therapy. Recent years,large molecular, HSP 110 was found to has the unique adjuvant effect since its powerful moleeular chaperoning function, thus was thought to has wide application perspective in the preparation of tumor racine and anti-tumor immunity.
作者 单彩凤
出处 《国际免疫学杂志》 CAS 2007年第4期213-216,共4页 International Journal of Immunology
基金 国家重大基础研究计划“973”免疫学项目(2001CB510002)
关键词 HSP110 抗原提呈细胞 佐剂 肿瘤免疫治疗 HSP110 APC Adjuvant Anti-tumor immune therapy
  • 相关文献

参考文献17

  • 1郭建巍.HSP—肿瘤免疫的分子佐剂[J].国外医学(免疫学分册),2002,25(4):181-184. 被引量:3
  • 2施海燕,顾君一,张天一,林琳,朱昌来.HSPgp96体外诱导腹腔巨噬细胞抗肿瘤细胞毒作用[J].中国肿瘤生物治疗杂志,2005,12(4):272-274. 被引量:1
  • 3杨峰,万涛,周向阳,吴艳峰,李楠,陈国友,蒋应明,曹雪涛.HSP70L1与OVA融合蛋白的制备及其生物学功能的初步研究[J].中国肿瘤生物治疗杂志,2006,13(2):129-134. 被引量:2
  • 4Lee-Yoon D, Easton D, Murawski M, et ah Identification of a major subfamily of large Hsp70-like proteins through the cloning of the mammalian 110-kDa heat shock protein. Biol Chemi, 1995, 270 ( 26 ) : 15725-15733.
  • 5Chen X, Easton D, Oh HJ,et al. The 170kDa glucose regulated stress protein is a large Hsp70-, Hsp110-like protein of the endoplasmic reticulum. FEBS Lett, 1996, 380(1-2) :68-72.
  • 6Oh HJ, Easton D, Murawski M, et al. The chaperoning activity of Hsp110:identification of functional domains by use of targeted deletions. J Biol Chem, 1999,274(22):15712-15718.
  • 7Hwang TS, Han HS, Choi HK, et al. Differenial,stage-dependent expression of Hsp70, Hsp110 and Bcl-2 in colorectal cancer Res. J Gastroenterol Hepatol,2003, 18 ( 6 ) : 690 -700.
  • 8Manjili MH,Henderson R,Wang XY,et al. Development of a recombinant Hsp110-HER-2/neu vaccine using the chaperoning properties of Hsp110. Cancer Res,2002, 62 (6) : 1737-1742.
  • 9Manjili MH,Wang XY, Chen X, et al. Hsp110-Her2/neu chaperone complex vaccine induces protective immunity against spontaneous mammary tumors in Her-2/neu transgenic mice. J Immunol, 2003, 171 (8) :4054-4061.
  • 10Manjili MH,Park J,Facciponte JG,et al. HSP110 induces "danger singals" upon interaction with antigen presenting cells and mouse mammary carcinoma. Immunobiology,2005,210 ( 5 ) :295-303.

二级参考文献45

  • 1施海燕,周欣阳,张天一,林琳,吴坚,顾君一.HSPgp96与rIL-2治疗小鼠H22肝癌移植瘤的实验研究[J].南通医学院学报,2004,24(2):122-124. 被引量:1
  • 2Khanna R.[J]. Immunology and Cell Biology, 1998, 76(1): 20-26.
  • 3Melcher A, Tochyk S, Hardwick. [J]. Nat Med, 1998, 4(5): 581-587.
  • 4Wu Wz, Liu KD, Xie Q, et al.[J].J Exp Cancer Res, 1999,18(4): 543-547.
  • 5Fisch P, Malkovsky M, Kovats S, et al.[J].Science, 1990,250(4985): 1269-1273.
  • 6Kim HT, Nelson EL, Clayberger C, et al. [J]. J Immunol, 1995, 154 (4): 1614-1623.
  • 7Breloer M, Fleischer B, vonBovin. [J]. The Joumal of Immunology, 1999, 162(6): 3141-3147.
  • 8Suzue K, Zhou X, Eisen HN, et al. [J]. Natl Acad Sci USA, 1997,94 (24): 13146-13181.
  • 9Barrios C, Lussow AR, Van Emdben J, et al. [J]. Eur J Immunol, 1992, 22(6): 1368-1372.
  • 10Nathalie E, Blachere, Zhihai Li, et al. [J]. J Exp Med, 1997, 186 (8): 1315-1322.

共引文献3

同被引文献4

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部